Clinical Trial Update: Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. [Phase 2]

View source ↗

Summary

Phase 2 trial update of Jaktinib in relapsed/refractory myelofibrosis patients previously treated with ruxolitinib has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Jaktinib (jaktinib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED